New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
09:03 EDTBTXBioTime unit expands clinical development of bladder cancer test
BioTime and its subsidiary OncoCyte announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the U.S., has received Institutional Review Board approval at multiple sites and should begin enrolling patients within the next week. OncoCyte’s initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial is designed to expand the potential use of the PanC-Dx bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months. The goal of the current clinical trial is to compare the performance of OncoCyte’s proprietary PanC-Dx bladder cancer markers to the performance of cystoscopy.
News For BTX From The Last 14 Days
Check below for free stories on BTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
09:04 EDTBTXBioTime unit presents PanC-Dx data
Subscribe for More Information
September 17, 2014
09:04 EDTBTXBioTime unit receives OpRegen preclinical safety and efficacy study results
BioTime, HBL Hadasit Bio-Holdings and Cell Cure Neurosciences announced that Cell Cure has received the final results of a series of extensive preclinical safety and efficacy studies of its development-stage product designated OpRegen, which is intended for use in the treatment of dry form age-related macular degeneration. These studies were conducted by Cell Cure and contract research organizations in preparation for an IND filing with the Food and Drug Administration for a Phase 1/2a study in patients with geographic atrophy, the severe stage of dry-AMD. OpRegen is intended to be administered into the subretinal space of patients as a suspension of cells to treat this leading cause of blindness. The company said, "The protection of the animal’s vision from decay was dose dependent. As an additional indicator of therapeutic potential, the number of cone photoreceptors, which are responsible for fine vision in humans and are degenerating in the macula of dry-AMD patients, was found to remain constant over an extended period in the animal model.”
September 15, 2014
09:01 EDTBTXBioTime's OncoCyte unit announces collaboration with Abcodia
Subscribe for More Information
September 11, 2014
16:18 EDTBTXBioTime division partners with Cancer Research UK for lung cancer vaccine trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use